Navigation Links
Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
Date:10/24/2007

tly to tumor vasculature and tumor cells," said Mohammad Azab, M.D., president and chief executive officer of Intradigm. "The targeting of the VEGF pathway with RNAi represents a novel approach for anti-angiogenesis-based therapeutics, and with the tumor selectivity offered by our TargeTran(TM) system, we believe we are developing an innovative therapeutic candidate that may possess efficacy and/or safety advantages over existing or other anti-angiogenic agents in development."

ICS-283 is currently in preclinical development for a variety of cancer indications and the company expects to initiate clinical development of this candidate in 2008. The findings presented today support data from several other in vivo models, including xenograft models of different cancers, which have confirmed an RNAi-mediated anti-angiogenic effect following systemic administration similar to VEGF antibody. VEGF, as an established target in the treatment of cancer, provides a clear clinical development path to validate the success of Intradigm's systemic delivery of siRNA in man.

ABOUT INTRADIGM'S siRNA DELIVERY TECHNOLOGY

To address the issue of effective and targeted delivery of RNAi therapeutics, Intradigm has developed its proprietary RNAi Nanoplex(TM) technology, a powerful combination of advanced delivery systems. The RNAi Nanoplex(TM) technology is a multi-component delivery vector that carries active siRNA molecules in its core and in its targeted form (TargeTran(TM)) carries a ligand attached to its surface for specific tissue targeting. This platform is unique in its ability to offer tissue specific targeting of siRNA and intracellular delivery against the intracellular machinery of the target tissue. In addition, Intradigm also developed the PolyTran(TM) delivery system, a novel biodegradable polycation polymer that also shows great promise as an RNAi delivery system. Intradigm believes that this Nanoplex(TM) platform is one of the most versatile siRNA systemi
'/>"/>

SOURCE Intradigm Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Quebec , June 18, 2013 Valeant ... TSX: VRX) (the "Company") announced today that VPII Escrow ... the Company, has launched its offer of approximately $3.2 ... "Notes").  The Notes will be due in 2021 and ... The Company intends to use the net proceeds ...
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... 18, 2013  Millennium HealthCare Inc. (OTC Pink: ... an exclusive 25-year Supply and Distribution agreement for ... ("EWC") for its Distance Monitored Physical Therapy Program ... therapy program is a critical element in reducing ... Chris Amandola , president, Millennium HealthCare Inc.  ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3
(Date:6/19/2013)... that block the body,s system for repairing damage to ... As unlikely as it may seem, those compounds are ... cancers driven by a mutation in BRCA, a gene ... carries the mutation. The compounds, termed PARP inhibitors, are ... edition of Chemical & Engineering News . C&EN ...
(Date:6/19/2013)... Louisiana State University have developed a method for identifying ... on understanding the genetic interaction between single nucleotide polymorphisms ... cancer,s aggressiveness to avoid unnecessary radical treatment. , ... PLOS ONE in April. , According to the ... cancers and 9 percent of cancer deaths. It is ...
(Date:6/19/2013)... Alternatives, a revolutionary new treatment facility ... using drugs while allowing them to continue drinking alcohol. ... Alternatives, believe that abstinence-only approaches force people to wait ... that this approach hurts instead of helping. It ... States need treatment for addiction but only 3 million ...
(Date:6/19/2013)... Washington (PRWEB) June 19, 2013 ... physicians deem it medically necessary, according to a ... and Child Health Journal. The results of this ... for more than a decade – that trying-to-conceive ... and maintaining a healthy body weight. Fairhaven Health ...
(Date:6/19/2013)... Menopause International , suggests that post-menopausal women ... satisfying sex compared to their European and North ... to access appropriate treatment for a common, taboo ... called the CLarifying vaginal atrophy,s impact On SEx ... women with vaginal atrophy are more likely to ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:British women 50 percent less likley to recieve treatment for common menopausal symptoms 2
... Angeles, study the diet patterns in 52 normal weight people ... normal people generally ate more fruits and fibres than their ... the Journal of the American Dietetic Association stated that the ... and fruit intake, plays a role in the development of ...
... were related to drinking have more than doubled in Britain in ... yesterday by the Office for National Statistics (ONS) revealed has revealed ... in 2004. The statistics also showed that the alcohol related deaths ... is increasing in recent years. ,It was explained that ...
... in North Carolina and Virginia found evidence of pesticide ... call for pesticide safety training for workers’ spouses. ... Wake Forest University School of Medicine report that urine ... exposure than had been found in similar studies elsewhere. ...
... smoking in enclosed places and has put the draft regulation ... said that the government wanted to know about the people's ... and also said that it would be nice if the ... the Tories say that the plan would be expensive and ...
... be mandatory on all tobacco products soon failing which ... ,Other health warnings that could appear on ... pictorial representation of ill-effects of tobacco use and a ... headed by Anbumani Ramadoss, who has been a staunch ...
... has signed a memorandum of understanding (MOU) with the Clinton ... of affordable//, high- quality drugs as well as diagnostics for ... at the Presidential Villa with Nigerian President Olusegun Obasanjo and ... to Nigeria, as witnesses. ,According to the agreement, ...
Cached Medicine News:Health News:Better Weight Management Can be Achieved By Increased Intake Of Fibre & Fruits 2Health News:Research Documents Children’s Exposure to Pesticide 2
... Size: 3.0 x 7.5 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... Size: 4.0 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
For use with E5381 700 Circling Band (240 style). 1.65 mm diameter, 30.0 mm long....
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Medicine Products: